Search Result

Results for "

prostatic hyperplasia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5 alpha Reductase (5) Adrenergic Receptor (19) Apoptosis (2) Bacterial (1) Endogenous Metabolite (4) GnRH Receptor (1) Histamine Receptor (1) Isotope-Labeled Compounds (5) LPL Receptor (1) Pyruvate Kinase (1) Serotonin Transporter (2)
By Research Areas:	Cancer (17) Cardiovascular Disease (2) Endocrinology (18) Inflammation/Immunology (1) Metabolic Disease (5) Neurological Disease (6)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1442

AdTx1

Adrenergic Receptor Cancer

AdTx1 is a selective α1A-adrenoceptor antagonist (K_i: 0.35 nM). AdTx1 can be used for research of benign prostatic hyperplasia .

AdTx1	Adrenergic Receptor	Cancer
AdTx1 is a selective α1A-adrenoceptor antagonist (K_i: 0.35 nM). AdTx1 can be used for research of benign prostatic hyperplasia .

HY-P3501

Fexapotide NX-1207 free acid	Apoptosis	Cancer
Fexapotide (NX-1207 free acid) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .

HY-P3501A

Fexapotide TFA NX-1207 TFA	Apoptosis	Cancer
Fexapotide (NX-1207) TFA induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .

HY-B0391B

Naftopidil hydrochloride KT-611 hydrochloride; BM-15275 hydrochloride	Adrenergic Receptor	Cancer
Naftopidil hydrochloride (KT-611 hydrochloride) is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil hydrochloride has antiproliferative effects. Naftopidil hydrochloride can be used for the research of prostate hyperplasia .

HY-N8850

Angelol G	Others	Cancer
Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC₅₀ value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH) .

HY-B0391

Naftopidil KT-611; BM-15275	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia .

HY-B0391A

Naftopidil dihydrochloride KT-611 dihydrochloride; BM-15275 dihydrochloride	Adrenergic Receptor	Cancer
Naftopidil dihydrochloride (KT-611 dihydrochloride) is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil dihydrochloride has antiproliferative effects. Naftopidil dihydrochloride can be used for the research of prostate hyperplasia .

HY-B0661

Tamsulosin (R)-(-)-YM12617 free base; LY253351 free base	Adrenergic Receptor Endogenous Metabolite	Neurological Disease Endocrinology Cancer
Tamsulosin ((R)-(-)-YM12617 free base) is an inhibitor of α₁-adrenergic receptor. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth in animal models .

HY-B0371

Terazosin	Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0371F

Terazosin hydrochloride 4 Publications Verification	Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0371A

Terazosin hydrochloride dihydrate 4 Publications Verification	Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-107385

Epristeride ONO-9302; SKF105657	5 alpha Reductase	Cancer
Epristeride (ONO-9302) is a selective, specific and orally active uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. Epristeride has inhibitory effects for SR isoenzymes types 2 with K_i value of 0.7-2 nM. Epristeride can be used for the research of prostatic hyperplasia and acne .

HY-13635

Finasteride 4 Publications Verification MK-906	5 alpha Reductase	Cancer
Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .

HY-13635A

Finasteride acetate MK-906 acetate	5 alpha Reductase	Cancer
Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride acetate has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .

HY-103204

RS100329 hydrochloride	Adrenergic Receptor	Endocrinology
RS100329 hydrochloride is a potent and selective α1A-adrenoceptor antagonist with pK_i values of 9.6, 7.9 and 7.5 for α1A, α1D, and α1B, respectively. RS100329 hydrochloride inhibits reflex urethral contractions. RS100329 hydrochloride can be used in research of benign prostatic hyperplasia .

HY-115450

ONO-0300302	LPL Receptor	Endocrinology Cancer
ONO-0300302 is an orally active and potent LPA1 (lysophosphatidic acid receptor 1) antagonist, with an IC₅₀ of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with K_d of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research .

HY-105173

Teverelix EP 24332	GnRH Receptor Histamine Receptor	Endocrinology Cancer
Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer .

HY-B0192AS1

Alfuzosin-d7 hydrochloride SL 77499-10-d₇	Adrenergic Receptor	Endocrinology
Alfuzosin-d₇ (hydrochloride) is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-B0192A

Alfuzosin hydrochloride 1 Publications Verification SL 77499-10	Adrenergic Receptor	Endocrinology
Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .

HY-B0192

Alfuzosin SL 77499	Adrenergic Receptor	Endocrinology
Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .

HY-B0661A

Tamsulosin hydrochloride (R)-(-)-YM12617; LY253351	Adrenergic Receptor Endogenous Metabolite	Neurological Disease Endocrinology Cancer
Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α₁-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models .

HY-N8856

Angelol M	Others	Others
Angelol M,isolated from the roots of Angelica gigas Nakai, shows activity in inhibiting prostate specific antigen (PSA) secreted from androgen dependent prostate cancer cell line, LNCaP cells .

HY-B0192S

Alfuzosin-d7 SL 77499-d₇	Adrenergic Receptor	Endocrinology
Alfuzosin-d₇ is the deuterium labeled Alfuzosin[1]. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[2][3].

HY-B0391S1

Naftopidil-d5 KT-611-d₅; BM-15275-d₅	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease Endocrinology
Naftopidil-d₅ is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia[1][2].

HY-19702

PKR activator 3	Pyruvate Kinase	Metabolic Disease Inflammation/Immunology Cancer
PKR activator 3 is a pyruvate kinase isoform PKR activator extracted from patent WO2014139144A1, compound 160. PKR activator 3 can be used for the research of PKR function related diseases, including cancer, diabetes, obesity, autoimmune disorders, and benign prostatic hyperplasia .

HY-B0661AS

Tamsulosin-d5 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor Endogenous Metabolite	Neurological Disease Endocrinology
Tamsulosin-d₅ (hydrochloride) is the deuterium labeled Tamsulosin hydrochloride. Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models[1].

HY-B0661AS1

Tamsulosin-d4 hydrochloride (R)-(-)-YM12617-d₄; LY253351-d₄	Isotope-Labeled Compounds Adrenergic Receptor Endogenous Metabolite	Neurological Disease Endocrinology
Tamsulosin-d₄ (hydrochloride) is deuterium labeled Tamsulosin (hydrochloride). Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models[1].

HY-B0371S

Terazosin-d8	Isotope-Labeled Compounds Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin-d₈ is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].

HY-13635S

Finasteride-d9 MK-906-d₉	Isotope-Labeled Compounds 5 alpha Reductase	Cancer
Finasteride-d₉ is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia[1][2][3].

HY-13635R

Finasteride (Standard) MK-906 (Standard)	5 alpha Reductase	Cancer
Finasteride (Standard) is the analytical standard of Finasteride. This product is intended for research and analytical applications. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .

HY-135473

Chlormadinone

Others Others

Chlormadinone is an antiandrogen drug. Chlormadinone combined with Tamsulosin shows greater improvement in subjective symptoms of BPH .

Chlormadinone	Others	Others
Chlormadinone is an antiandrogen drug. Chlormadinone combined with Tamsulosin shows greater improvement in subjective symptoms of BPH .

HY-10122

Silodosin 2 Publications Verification KAD 3213; KMD 3213	Adrenergic Receptor Bacterial	Endocrinology Cancer
Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (K_i=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with K_i values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH .

HY-B0304A

Dapoxetine hydrochloride 1 Publications Verification LY-210448 hydrochloride	Serotonin Transporter	Neurological Disease
Dapoxetine (LY-210448) hydrochloride is an orally active and selective serotonin reuptake inhibitor (SSRI). Dapoxetine hydrochloride can be used for the research of premature ejaculation (PE) .

HY-B0304

Dapoxetine (S)-(+)-Dapoxetine; LY-210448	Serotonin Transporter	Neurological Disease
Dapoxetine (LY-210448) is an orally active and selective serotonin reuptake inhibitor (SSRI). Dapoxetine can be used for the research of premature ejaculation (PE) .

AdTx1	Adrenergic Receptor	Cancer
AdTx1 is a selective α1A-adrenoceptor antagonist (K_i: 0.35 nM). AdTx1 can be used for research of benign prostatic hyperplasia .

Fexapotide NX-1207 free acid	Apoptosis	Cancer
Fexapotide (NX-1207 free acid) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .

Teverelix EP 24332	GnRH Receptor Histamine Receptor	Endocrinology Cancer
Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0661

Tamsulosin (R)-(-)-YM12617 free base; LY253351 free base	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Endocrinology Cancer	Adrenergic Receptor Endogenous Metabolite
Tamsulosin ((R)-(-)-YM12617 free base) is an inhibitor of α₁-adrenergic receptor. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth in animal models .

HY-B0661A

Tamsulosin hydrochloride (R)-(-)-YM12617; LY253351	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Endocrinology	Adrenergic Receptor Endogenous Metabolite
Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α₁-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models .

HY-N8850

Angelol G	Structural Classification Leguminosae Campylotropis hirtella (Franch.) Schindl. Source classification Coumarins Phenylpropanoids Plants	Others
Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC₅₀ value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH) .

HY-B0371

Terazosin	Classification of Application Fields Disease Research Fields Endocrinology	Adrenergic Receptor
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-N8856

Angelol M	Structural Classification Leguminosae Campylotropis hirtella (Franch.) Schindl. Source classification Coumarins Phenylpropanoids Plants	Others
Angelol M,isolated from the roots of Angelica gigas Nakai, shows activity in inhibiting prostate specific antigen (PSA) secreted from androgen dependent prostate cancer cell line, LNCaP cells .

Cat. No.	Product Name	Chemical Structure

HY-B0192AS1

Alfuzosin-d7 hydrochloride
Alfuzosin-d₇ (hydrochloride) is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-B0192S

Alfuzosin-d7
Alfuzosin-d₇ is the deuterium labeled Alfuzosin[1]. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[2][3].

HY-B0391S1

Naftopidil-d5
Naftopidil-d₅ is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia[1][2].

HY-B0661AS

Tamsulosin-d5 hydrochloride
Tamsulosin-d₅ (hydrochloride) is the deuterium labeled Tamsulosin hydrochloride. Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models[1].

HY-B0661AS1

Tamsulosin-d4 hydrochloride
Tamsulosin-d₄ (hydrochloride) is deuterium labeled Tamsulosin (hydrochloride). Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models[1].

HY-B0371S

Terazosin-d8
Terazosin-d₈ is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].

HY-13635S

Finasteride-d9

Finasteride-d₉ is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia[1][2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

prostatic hyperplasia

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products